Literature DB >> 28060330

Hyperpolarized 13C Metabolic Magnetic Resonance Spectroscopy and Imaging.

Eugen Kubala1, Kim A Muñoz-Álvarez2, Geoffrey Topping2, Christian Hundshammer3, Benedikt Feuerecker2, Pedro A Gómez4, Giorgio Pariani5, Franz Schilling2, Steffen J Glaser6, Rolf F Schulte7, Marion I Menzel7, Markus Schwaiger2.   

Abstract

In the past decades, new methods for tumor staging, restaging, treatment response monitoring, and recurrence detection of a variety of cancers have emerged in conjunction with the state-of-the-art positron emission tomography with 18F-fluorodeoxyglucose ([18F]-FDG PET). 13C magnetic resonance spectroscopic imaging (13CMRSI) is a minimally invasive imaging method that enables the monitoring of metabolism in vivo and in real time. As with any other method based on 13C nuclear magnetic resonance (NMR), it faces the challenge of low thermal polarization and a subsequent low signal-to-noise ratio due to the relatively low gyromagnetic ratio of 13C and its low natural abundance in biological samples. By overcoming these limitations, dynamic nuclear polarization (DNP) with subsequent sample dissolution has recently enabled commonly used NMR and magnetic resonance imaging (MRI) systems to measure, study, and image key metabolic pathways in various biological systems. A particularly interesting and promising molecule used in 13CMRSI is [1-13C]pyruvate, which, in the last ten years, has been widely used for in vitro, preclinical, and, more recently, clinical studies to investigate the cellular energy metabolism in cancer and other diseases. In this article, we outline the technique of dissolution DNP using a 3.35 T preclinical DNP hyperpolarizer and demonstrate its usage in in vitro studies. A similar protocol for hyperpolarization may be applied for the most part in in vivo studies as well. To do so, we used lactate dehydrogenase (LDH) and catalyzed the metabolic reaction of [1-13C]pyruvate to [1-13C]lactate in a prostate carcinoma cell line, PC3, in vitro using 13CMRSI.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 28060330      PMCID: PMC5226623          DOI: 10.3791/54751

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  76 in total

1.  On the origin of cancer cells.

Authors:  O WARBURG
Journal:  Science       Date:  1956-02-24       Impact factor: 47.728

2.  Transmit gain calibration for nonproton MR using the Bloch-Siegert shift.

Authors:  Rolf F Schulte; Laura Sacolick; Martin H Deppe; Martin A Janich; Markus Schwaiger; Jim M Wild; Florian Wiesinger
Journal:  NMR Biomed       Date:  2011-03-08       Impact factor: 4.044

3.  Kinetic modeling of hyperpolarized 13C1-pyruvate metabolism in normal rats and TRAMP mice.

Authors:  Matthew L Zierhut; Yi-Fen Yen; Albert P Chen; Robert Bok; Mark J Albers; Vickie Zhang; Jim Tropp; Ilwoo Park; Daniel B Vigneron; John Kurhanewicz; Ralph E Hurd; Sarah J Nelson
Journal:  J Magn Reson       Date:  2009-10-13       Impact factor: 2.229

4.  PET/CT in patients with hepatocellular carcinoma using [(18)F]fluorocholine: preliminary comparison with [(18)F]FDG PET/CT.

Authors:  Jean-Noël Talbot; Fabrice Gutman; Laetitia Fartoux; Jean-Didier Grange; Nathalie Ganne; Khaldoun Kerrou; Dany Grahek; Françoise Montravers; Raoul Poupon; Olivier Rosmorduc
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-06-27       Impact factor: 9.236

5.  Imaging of blood flow using hyperpolarized [(13)C]urea in preclinical cancer models.

Authors:  Cornelius von Morze; Peder E Z Larson; Simon Hu; Kayvan Keshari; David M Wilson; Jan Henrik Ardenkjaer-Larsen; Andrei Goga; Robert Bok; John Kurhanewicz; Daniel B Vigneron
Journal:  J Magn Reson Imaging       Date:  2011-03       Impact factor: 4.813

6.  Comparison of kinetic models for analysis of pyruvate-to-lactate exchange by hyperpolarized 13 C NMR.

Authors:  Crystal Harrison; Chendong Yang; Ashish Jindal; Ralph J DeBerardinis; M A Hooshyar; Matthew Merritt; A Dean Sherry; Craig R Malloy
Journal:  NMR Biomed       Date:  2012-03-26       Impact factor: 4.044

7.  Production of hyperpolarized [1,4-13C2]malate from [1,4-13C2]fumarate is a marker of cell necrosis and treatment response in tumors.

Authors:  Ferdia A Gallagher; Mikko I Kettunen; De-En Hu; Pernille R Jensen; René In 't Zandt; Magnus Karlsson; Anna Gisselsson; Sarah K Nelson; Timothy H Witney; Sarah E Bohndiek; Georg Hansson; Torben Peitersen; Mathilde H Lerche; Kevin M Brindle
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-10       Impact factor: 11.205

8.  Detecting tumor response to treatment using hyperpolarized 13C magnetic resonance imaging and spectroscopy.

Authors:  Sam E Day; Mikko I Kettunen; Ferdia A Gallagher; De-En Hu; Mathilde Lerche; Jan Wolber; Klaes Golman; Jan Henrik Ardenkjaer-Larsen; Kevin M Brindle
Journal:  Nat Med       Date:  2007-10-28       Impact factor: 53.440

9.  3D CMR mapping of metabolism by hyperpolarized 13C-pyruvate in ischemia-reperfusion.

Authors:  Giovanni Donato Aquaro; Francesca Frijia; Vincenzo Positano; Luca Menichetti; Maria Filomena Santarelli; Jan Henrik Ardenkjaer-Larsen; Florian Wiesinger; Vincenzo Lionetti; Simone Lorenzo Romano; Giacomo Bianchi; Danilo Neglia; Giulio Giovannetti; Rolf F Schulte; Fabio Anastasio Recchia; Luigi Landini; Massimo Lombardi
Journal:  JACC Cardiovasc Imaging       Date:  2013-06

10.  High-Field Dynamic Nuclear Polarization for Solid and Solution Biological NMR.

Authors:  A B Barnes; G De Paëpe; P C A van der Wel; K-N Hu; C-G Joo; V S Bajaj; M L Mak-Jurkauskas; J R Sirigiri; J Herzfeld; R J Temkin; R G Griffin
Journal:  Appl Magn Reson       Date:  2008-08       Impact factor: 0.831

View more
  3 in total

Review 1.  Multiorgan, Multimodality Imaging in Cardiometabolic Disease.

Authors:  Vidhya Kumar; Willa A Hsueh; Subha V Raman
Journal:  Circ Cardiovasc Imaging       Date:  2017-11       Impact factor: 7.792

2.  Assessment of 213Bi-anti-EGFR MAb treatment efficacy in malignant cancer cells with [1-13C]pyruvate and [18F]FDG.

Authors:  Benedikt Feuerecker; Michael Michalik; Christian Hundshammer; Markus Schwaiger; Frank Bruchertseifer; Alfred Morgenstern; Christof Seidl
Journal:  Sci Rep       Date:  2019-06-05       Impact factor: 4.379

Review 3.  Metabolism, HDACs, and HDAC Inhibitors: A Systems Biology Perspective.

Authors:  Jacob King; Maya Patel; Sriram Chandrasekaran
Journal:  Metabolites       Date:  2021-11-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.